The value of epithelial membrane antigen overexpression in hyperplastic and malignant endometrium and its relationship with steroid hormone receptor expression

The aim of this study was to evaluate the value of epithelial membrane antigen overexpression (EMA OE) in benign, hyperplastic and neoplastic endometrium and to analyze its association with estrogen and progesterone receptors (ER, PR) immunohistochemistry, tumor grade and myometrial invasion in patients with endometrial carcinoma (EC). The OE of EMA was analysed immunohistochemically in nine patients with benign endometrium (BE), in 18 patients with atypical complex endometrial hyperplasia (ACH) and in 29 patients with EC. EMA OE was present in 13 of 29 patients (44.8%) with EC, in two of 18 patients (11.1 %) with ACH, and in none of nine patients with BE (p < 0.05). EMA OE of endometrial carcinoma was statistically correlated with the International Federation of Gynecology and Obstetrics (FIGO) grade (G1 vs G2 and G3, p < 0.05) and depth of myometrial invasion (< 1/2 vs > 1/2, p < 0.05). EMA OE was significantly associated with PR negativity (p < 0.001). However it did not show any association with ER immunohistochemistry (p = 0.14). PR immunohistochemistry had significant correlations with FIGO grade (p < 0.001) and depth of myometrial invasion (p < 0.05) but ER loss showed a nearly significant association only with advanced FIGO grade (p = 0.054). In conclusion, EMA shows increased expression as the lesion progresses to malignancy and can also aid discrimination between hyperplastic and neoplastic states. The correlation of imunohistochemical findings with tumor grade and myometrial invasion could help in predicting behavior of the tumor and planning treatment in patients with endometrial carcinoma.

Endometrial cancer; Epithelial membrane antigen; Estrogen receptors; Progesterone receptors

[1] Fukuda K., Mori M., Uchiyama M., Iwai K., Iwasaka T., Sugirnon H.: "Prognostic significance of progesterone receptor irnrnunohistochernistry in endornetrial carcinoma". Gynecol. Oneal., 1998, 69, 220.

[2] Kounelis S., Kapranos N., Kouri E., Coppola D., Papadaki H., Jones M.W.: "Irnrnunohistochernical profile of endornetrial adenocarcinoma: a study of 61 cases and review of the literature". Mod. Pathol., 2000, 13, 379.

[3] Sivridis E., Giatromanolaki A., Koukourakis M., Anastasiadis P.: "Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression". Wirhows Arch., 2001, 438, 470.

[4] Pertschuk L.P., Masood S., Simone J., Feldman J.G., Fruchter R.G., Axiol!s C.A., Greene G.L.: "Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival". Gynecol. Oneal., 1996, 63, 28.

[5] Bell J.G., Minnick A., Reid G.C., Judis J., Brownell M.: "Relationship of nonstaging risk factors to lymph node metastasis and recurrence in clinical Stage I endometrial carcnoma". Gynecol Oneal., 1997, 66, 388.

[6] Morris P.C., Anderson J.R., Anderson B., Buller R.E.: "Steroid hormone receptor content and lymph node status in endometrial cancer". Gynecol. Oneal., 1995, 56, 406.

[7] Iwai K., Fukuda K., Hachisuga T., Mori M., Uchiyama M., Iwasaka T., Sugimori H.: "Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma". Gynecol. Oneal., 1999, 72, 351.

[8] Bozdogan O., Atasoy P., Erekul S., Bozdogan N., Bayram M.: "Apoptosis-related proteins abd sterois hormone receptors in normal, hyperplastic, and neoplastic endometrium". Int. J. Gynecol. Pathol., 2002, 21, 375.

[9] Papadimitrou C.S., Athanasiadou S., Stylianidou A., Bai M.K., Demoliatis J., Stephanou D.G.: "Immunohistochemical detection of estrogen receptors on paraffin sections of normal, hyperplastic and carcinomatous endometrium". Oneal., 1992, 49, 196.

[10] Huang S.J., Cheng K.J., Lewin and Yao S.F.: "Immunohistochemical estrogen receptor assessment in hyperpalstic, neoplastic and physiologic endometria". Path. Res. Pract., 1991, 187, 487.

[11] Snijders M.P., de Goeij A.F., Koudstaal J., Thunnissen E.B., de Haan J., Bosman F.T.: " Oestrogen and progesterone receptor immunocytochemistry in human hyperplastic and neoplastic endometrium". J. Pathol., 1992, 166, 171.

[12] Brustein S., Fruchter R., Greene G.L., Pertschuk L.P.: "Immunocytochemical assay of progesterone receptors in paraffin-embedded specimens of endometrial carcinoma and hyperplasia: a preliminary evaluation". Mod. Pathol., 1989, 2, 449.

[13] Bergeron C., Ferenezy A., Toft D.O., Shyamala G.: "Immunocy tochemical study of progesterone receptors in hyperplastic and neoplastic endometrial tissues". Cancer Res., 1988, 48, 6132.

[14] Chambers J.T., MacLusky N., Eisenfield A., Kohorn E.I.. Lawrence R., Schwartz P.E.: "Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer". Gynecol. Oneal., 1988, 31, 65.

[15] Coronado P.J., Fasero M., Vidart J.A., Puerta J., Magrina J., FunoBacete V., Ascudero M.: "A comparison of epithelial membrane antigen overexpression in benign and malignant endometrium" Gynecol. Oneal., 2001, 82, 483.

[16] Heyderman E., Strudley I., P owell G., Richardson T.C., Cordell J.I., Mason D.Y.: "A new monoclonal antibody to epithelial mambrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with poliyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2". Br. J. Cancer, 1985, 52, 355.

[17] To A., Coleman D.V., Dearney D.f'.., Ormerod M.G., Steele K., Neville A.M.: "Use of antisera to epithelial membrane antigen for the cytodiagnosis of malignancy in serous effusions". J. Clin. Pathol., 1981. 34, 1326.

[18] Pinkus G.S., Kurtin P.J.: "Epithelial membrane antigen - a d1agnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesencymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies". Hum. Pathol., 1985, 16, 929.

[19] Nakopoulou L., Minaertzis D., Tsionou C.H., Mastrominas M.: "Value of immunohistochemical demonstration of several epithelial markers in hyperplastic and neopalstic endometrium". Gynecol. Oneal., 1990, 37, 346.

[20] Morse A.R., Curran G.J.: "Distribution of epithelial membrane antigen in normal and abnormal endometrium tissue". Br. J. Obstet. Gynaecol., 1985, 92, 1286.

[21] Carcangiu M.L., Chambers J.T., Voynick I.M.，Pirro M., Schwartz P.E.: "Immunohistochemicai evaluation of estrogen and progeserone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations". Am. J. Clin. Pathol., 1990, 94, 247.

[22] Li S.F., Shiozama T., Nakayama K., Nikaido T., Fujii S.: "Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb) and cyclin E in uterine endometrioid carcinoma". Cancer, 1996, 77, 321.

[23] Soper J.T., Christensen C.W.: "Steroid receptors and endometrial cancer". Clin. Obstet. Gynaecol., 1986, 825.

[24] Yamauchi N., Sakamato A., Uozaki H., Iihara K., Mochinami R.: "Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p 53 in relation to expression of sex steroid receptor and proliferative activity". Int. J. Gynecol. Pathol., 1996, 15, 202.

[25] Heyderman E., Steele K., Ormerod M.G.: "A new antigen on the epithelial membrane: its immunoperoxidase localisation in normal and neoplastic tissue". J. Clin. Pathol., 1979, 32, 35.

[26] Tabibzadeh S.: "Immunoreactivity of human endometrium: corrrelation with endometrial dating". Fertil. Steril., 1990, 54, 624.

[27] Bergquist A., Kerno M.: "Oestrogen and progesterone receptors in endometriotic tissue and endometrium: comparison of different cycle phases and ages". Hum. Reprod., 1993, 8, 2211.